drugset / Trial / NCT00514306

Study of Intermittent OSI-906 Dosing

NCT00514306

Phase 1 Completed 79 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.

Timeline

Start
2007-07-05
Primary completion
2010-09-20
Completion
2010-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject linsitinib Small molecule Oral

Indications